NYSE:MAIA
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. reported net income of −$22.4M in fiscal 2025. The diluted share count rose 44.7%.Summary generated from MAIA Biotechnology, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−745.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+44.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 0 | n/a |
| Operating income | −8 | −16 | −20 | −17 | −24 |
| Net income | −13 | −16 | −20 | −23 | −22 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Oct 6, 2026 - 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of a shareholder vote
May 22, 2026 - 8-KTermination of a material agreement
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026 - 8-KOther events
Apr 16, 2026